Sotrovimab
thumb|140px|A vial of Sotrovimab Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.tradename
- Xevudy
- Drug.MedlinePlus
- a621037
- Drug.DailyMedID
- Sotrovimab
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BD05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
Article
10 sectionsContents
- Medical uses
- Development and mechanism of action
- Clinical efficacy
- Manufacturing
- Society and culture
- Economics
- Legal status
- Research
- References
- External links
thumb|140px|A vial of Sotrovimab Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.
The most common side effects include hypersensitivity (allergic) reactions and infusion-related reactions.